SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. You have free access to this content1
    Paul Martin, Andrea DiMartini, Sandy Feng, Robert Brown, Michael Fallon, Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation, Hepatology, 2014, 59, 3
  2. 2
    David S. Goldberg, Karen Krok, Sachin Batra, James F. Trotter, Steven M. Kawut, Michael B. Fallon, Impact of the Hepatopulmonary Syndrome MELD Exception Policy on Outcomes of Patients After Liver Transplantation: An Analysis of the UNOS Database, Gastroenterology, 2014, 146, 5, 1256

    CrossRef

  3. 3
    Laura Lladó, Javier Bustamante, IV Reunión de Consenso de la Sociedad Española de Trasplante Hepático 2012. Excepciones al Model for End-stage Liver Disease en la priorización para trasplante hepático, Gastroenterología y Hepatología, 2014, 37, 2, 83

    CrossRef

  4. 4
    D. S. Goldberg, S. Batra, S. Sahay, S. M. Kawut, M. B. Fallon, MELD Exceptions for Portopulmonary Hypertension: Current Policy and Future Implementation, American Journal of Transplantation, 2014, 14, 9
  5. 5
    Adam Deising, Rohit Satoskar, MELD: Which Patients Fall Through the Cracks?, Current Hepatology Reports, 2014, 13, 1, 60

    CrossRef

  6. 6
    Johannes Klose, Michelle A. Klose, Courtney Metz, Frank Lehner, Michael P. Manns, Juergen Klempnauer, Nils Hoppe, Harald Schrem, Alexander Kaltenborn, Outcome stagnation of liver transplantation for primary sclerosing cholangitis in the Model for End-Stage Liver Disease era, Langenbeck's Archives of Surgery, 2014,

    CrossRef

  7. 7
    Reena J. Salgia, Nathan P. Goodrich, Heather Simpson, Robert M. Merion, Pratima Sharma, Outcomes of Liver Transplantation for Porto-Pulmonary Hypertension in Model for End-Stage Liver Disease Era, Digestive Diseases and Sciences, 2014, 59, 8, 1976

    CrossRef

  8. 8
    D. Ghinolfi, J. Marti, P. De Simone, Q. Lai, D. Pezzati, L. Coletti, D. Tartaglia, G. Catalano, G. Tincani, P. Carrai, D. Campani, M. Miccoli, G. Biancofiore, F. Filipponi, Use of Octogenarian Donors for Liver Transplantation: A Survival Analysis, American Journal of Transplantation, 2014, 14, 9
  9. 9
    Rena K. Fox, When to Consider Liver Transplant During the Management of Chronic Liver Disease, Medical Clinics of North America, 2014, 98, 1, 153

    CrossRef

  10. 10
    Michael L. Volk, Center differences in model for end-stage liver disease exceptions: Fairness, local culture, and norms of practice, Liver Transplantation, 2013, 19, 12
  11. 11
    David S. Goldberg, George Makar, Therese Bittermann, Benjamin French, Center variation in the use of nonstandardized model for end-stage liver disease exception points, Liver Transplantation, 2013, 19, 12
  12. 12
    Tom J. G. Gevers, Joost P. H. Drenth, Diagnosis and management of polycystic liver disease, Nature Reviews Gastroenterology & Hepatology, 2013, 10, 2, 101

    CrossRef

  13. 13
    Andres F. Carrion, Kalyan Ram Bhamidimarri, Liver Transplant for Cholestatic Liver Diseases, Clinics in Liver Disease, 2013, 17, 2, 345

    CrossRef

  14. 14
    Rodrigo Liberal, Yoh Zen, Giorgina Mieli-Vergani, Diego Vergani, Liver transplantation and autoimmune liver diseases, Liver Transplantation, 2013, 19, 10
  15. You have free access to this content15
    Joel P. Wedd, Ann M. Harper, Scott W. Biggins, MELD score, allocation, and distribution in the United States, Clinical Liver Disease, 2013, 2, 4
  16. 16
    David S. Goldberg, Michael B. Fallon, Model for End-Stage Liver Disease–Based Organ Allocation: Managing the Exceptions to the Rules, Clinical Gastroenterology and Hepatology, 2013, 11, 5, 452

    CrossRef

  17. 17
    Russell H. Wiesner, Moving toward evidence-based liver allocation in patients with primary sclerosing cholangitis, Liver Transplantation, 2013, 19, 3
  18. 18
    Michael J. Krowka, Russell H. Wiesner, Julie K. Heimbach, Pulmonary contraindications, indications and MELD exceptions for liver transplantation: A contemporary view and look forward, Journal of Hepatology, 2013, 59, 2, 367

    CrossRef

  19. 19
    David S. Goldberg, Amanda Camp, Alvaro Martinez-Camacho, Lisa Forman, Brett Fortune, K. Rajender Reddy, Risk of waitlist mortality in patients with primary sclerosing cholangitis and bacterial cholangitis, Liver Transplantation, 2013, 19, 3
  20. 20
    Richard B. Freeman, A decade of model for end-stage liver disease, Current Opinion in Organ Transplantation, 2012, 17, 3, 211

    CrossRef

  21. 21
    Swastik Agrawal, Radha K Dhiman, Answers to Multiple Choice Questions, Journal of Clinical and Experimental Hepatology, 2012, 2, 2, 200

    CrossRef

  22. 22
    Therese Bittermann, George Makar, David Goldberg, Exception point applications for 15 points: An unintended consequence of the Share 15 policy, Liver Transplantation, 2012, 18, 11
  23. 23
    Paolo Angeli, Pere Gines, Hepatorenal syndrome, MELD score and liver transplantation: An evolving issue with relevant implications for clinical practice, Journal of Hepatology, 2012, 57, 5, 1135

    CrossRef

  24. 24
    D. Goldberg, T. Bittermann, G. Makar, Lack of Standardization in Exception Points for Patients With Primary Sclerosing Cholangitis and Bacterial Cholangitis, American Journal of Transplantation, 2012, 12, 6
  25. 25
    M. Macchiaiolo, A. Bartuli, P. McKiernan, C. Dionisi-Vici, J. de Ville de Goyet, Too late to say it is too early – How to get children with non-cirrhotic metabolic diseases transplanted at the right time?, Pediatric Transplantation, 2012, 16, 7
  26. 26
    Patrizia Burra, Richard Freeman, Trends in liver transplantation 2011, Journal of Hepatology, 2012, 56, S101

    CrossRef

  27. 27
    Stevan A. Gonzalez, Emmet B. Keeffe, Handbook of Liver Disease, 2012,

    CrossRef

  28. 28
    Mohamad R. Al Sibae, Mitchell S. Cappell, Accuracy of MELD Scores in Predicting Mortality in Decompensated Cirrhosis from Variceal Bleeding, Hepatorenal Syndrome, Alcoholic Hepatitis, or Acute Liver Failure As Well As Mortality After Non-transplant Surgery or TIPS, Digestive Diseases and Sciences, 2011, 56, 4, 977

    CrossRef

  29. 29
    Salvatore Piano, Filippo Morando, Silvano Fasolato, Marta Cavallin, Novella Boscato, Patrizia Boccagni, Giacomo Zanus, Umberto Cillo, Angelo Gatta, Paolo Angeli, Continuous recurrence of type 1 hepatorenal syndrome and long-term treatment with terlipressin and albumin: A new exception to MELD score in the allocation system to liver transplantation?, Journal of Hepatology, 2011, 55, 2, 491

    CrossRef

  30. You have free access to this content30
    Robert M. Merion, Pratima Sharma, Amit K. Mathur, Douglas E. Schaubel, Evidence-based development of liver allocation: a review, Transplant International, 2011, 24, 10
  31. 31
    Rita Garcia-Martinez, Alex Rovira, Juli Alonso, Carlos Jacas, Macarena Simón-Talero, Laia Chavarria, Víctor Vargas, Juan Córdoba, Hepatic encephalopathy is associated with posttransplant cognitive function and brain volume, Liver Transplantation, 2011, 17, 1
  32. 32
    Jawad A. Ilyas, Christine A. O’Mahony, John M. Vierling, Liver transplantation in autoimmune liver diseases, Best Practice & Research Clinical Gastroenterology, 2011, 25, 6, 765

    CrossRef

  33. 33
    A. B. Massie, B. Caffo, S. E. Gentry, E. C. Hall, D. A. Axelrod, K. L. Lentine, M. A. Schnitzler, A. Gheorghian, P. R. Salvalaggio, D. L. Segev, MELD Exceptions and Rates of Waiting List Outcomes, American Journal of Transplantation, 2011, 11, 11
  34. 34
    Kenneth Washburn, Model for end-stage liver disease exceptions: Proceed with caution, Liver Transplantation, 2011, 17, 10
  35. 35
    C. K. Argo, G. J. Stukenborg, T. M. Schmitt, S. C. Kumer, C. L. Berg, P. G. Northup, Regional Variability in Symptom-Based MELD Exceptions: A Response to Organ Shortage?, American Journal of Transplantation, 2011, 11, 11
  36. 36
    F. Temmerman, L. Missiaen, B. Bammens, W. Laleman, D. Cassiman, C. Verslype, J. van Pelt, F. Nevens, Systematic review: the pathophysiology and management of polycystic liver disease, Alimentary Pharmacology & Therapeutics, 2011, 34, 7
  37. 37
    Mauro Bernardi, Stefano Gitto, Maurizio Biselli, The MELD score in patients awaiting liver transplant: Strengths and weaknesses, Journal of Hepatology, 2011, 54, 6, 1297

    CrossRef

  38. 38
    Lainie Friedman Ross, An Ethical and Policy Analysis of Elective Transplantation for Metabolic Conditions Diagnosed by Newborn Screening, The Journal of Pediatrics, 2010, 156, 1, 139

    CrossRef

  39. 39
    Andrew T Burr, Shimul A Shah, Disparities in organ allocation and access to liver transplantation in the USA, Expert Review of Gastroenterology & Hepatology, 2010, 4, 2, 133

    CrossRef

  40. 40
    Sharon B. Mathews, Wanda Allison, Sonia Lin, Liver Transplant Considerations for Evaluation, CTP, and MELD, Critical Care Nursing Clinics of North America, 2010, 22, 3, 403

    CrossRef

  41. 41
    Norberto Sotelo, Pediatric viral hepatitis: avoiding liver failure, Pediatric Health, 2010, 4, 6, 613

    CrossRef

  42. 42
    Ulf Hemprich, Peter J Papadakos, Burkhard Lachmann, Respiratory failure and hypoxemia in the cirrhotic patient including hepatopulmonary syndrome, Current Opinion in Anaesthesiology, 2010, 23, 2, 133

    CrossRef

  43. 43
    Consensus document of the Spanish Society of Liver Transplantation. Waiting lists, liver transplantation, and quality indicators, Cirugía Española (English Edition), 2009, 86, 6, 331

    CrossRef

  44. 44
    W. Patkowski, K. Zieniewicz, M. Skalski, M. Krawczyk, Correlation Between Selected Prognostic Factors and Postoperative Course in Liver Transplant Recipients, Transplantation Proceedings, 2009, 41, 8, 3091

    CrossRef

  45. 45
    Documento de consenso de la Sociedad Española de Trasplante Hepático. Lista de espera, trasplante pediátrico e indicadores de calidad, Gastroenterología y Hepatología, 2009, 32, 10, 702

    CrossRef

  46. 46
    Documento de consenso de la Sociedad Española de Trasplante Hepático. Lista de espera, trasplante pediátrico e indicadores de calidad, Cirugía Española, 2009, 86, 6, 331

    CrossRef

  47. 47
    Juan F. Gallegos-Orozco, Hugo E. Vargas, Liver Transplantation: From Child to MELD, Medical Clinics of North America, 2009, 93, 4, 931

    CrossRef

  48. 48
    Michele Barone, Alfonso W. Avolio, Alfredo Di Leo, Patrizia Burra, Antonio Francavilla, ABO Blood Group-Related Waiting List Disparities in Liver Transplant Candidates: Effect of the MELD Adoption, Transplantation, 2008, 85, 6, 844

    CrossRef

  49. 49
    Jacqueline G. O'Leary, Rita Lepe, Gary L. Davis, Indications for Liver Transplantation, Gastroenterology, 2008, 134, 6, 1764

    CrossRef

  50. 50
    Keli Hansen, Simon Horslen, Metabolic liver disease in children, Liver Transplantation, 2008, 14, 4
  51. 51
    Keli Hansen, Simon Horslen, Metabolic liver disease in children, Liver Transplantation, 2008, 14, 5
  52. 52
    Richard B. Freeman, Model for end-stage liver disease (MELD) for liver allocation: A 5-year score card, Hepatology, 2008, 47, 3
  53. 53
    Mark W Russo, Current concepts in the evaluation of patients for liver transplantation, Expert Review of Gastroenterology & Hepatology, 2007, 1, 2, 307

    CrossRef

  54. 54
    James F Trotter, Impact of the Model for Endstage Liver Disease score on liver transplantation, Current Opinion in Organ Transplantation, 2007, 12, 3, 294

    CrossRef

  55. 55
    Richard B. Freeman, The Model for End-stage Liver Disease Comes of Age, Clinics in Liver Disease, 2007, 11, 2, 249

    CrossRef

  56. 56
    James F. Trotter, Controversies in Liver Transplantation,
  57. 57
    Nicole Siparsky, David Axelrod, Richard B. Freeman, Organ Allocation in Liver Transplantation: Ethics, Organ Supply, and Evidencebased Practice,
  58. 58
    Audrey Coilly, Didier Samuel, Selection and Evaluation of the Recipient (Including Retransplantation),